Melbourne-based mental health technology company Medibio (ASX:MEB) has announced a 'Sponsored Research Agreement' with the Department of Biomedical Sciences of Humanitas University in Milan.

Immuron (ASX:IMC) has announced the appointment of its CEO, Dr Gary Jacob, to the Board of Directors.

"Novartis is delighted about today’s announcement and the difference this therapy will make to patients in Australia," said Lauren Carey, general manager Oncology and country president, Novartis Australia and New Zealand.

Wearisome uncertainty continues for industry as the Research and Development Tax Initiative (RDTI) was not explicitly mentioned in the 2019 Budget announcements, but the numbers appear to assume the Bill to change the RDTI will go ahead under a Coalition government.

MGC Pharmaceuticals (ASX:MXC) says it has received a UK Controlled Drug Import Licence permit for the importation of CannEpil.

The company said the implant is designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet.

Leading digital health company ResApp Health (ASX:RAP) has announced it has submitted an application to the US FDA for De Novo classification of its ResAppDx-US - a mobile software application for the diagnosis of paediatric respiratory disease using cough sounds.